Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen (TA1087)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 August 2025
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 March 2025
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) (TA938)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 December 2023
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 October 2021
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 October 2019
Omalizumab for previously treated chronic spontaneous urticaria (TA339)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 June 2015
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013